Optimizing Clinical Development Success In Hematologic Malignancies

By Louise Scott, PhD, Senior Director, Therapeutic Strategy Lead, Oncology

Blood cancers are among the fastest-moving areas of oncology research. They are also among the hardest to treat with new therapies. Leukemia, lymphoma, and myeloma each have dozens of distinct subtypes defined by genetic changes. These cancers can also shift and transform during a trial, changing the very population being studied. New treatment types such as CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates are delivering strong results. Each, however, brings demanding requirements for safety monitoring, logistics, and specialized sites.

This article explains what sets blood cancer trials apart and how sponsors can plan for it, closing with a practical checklist of questions to answer before a trial starts. Read on to identify the design and operational gaps that could stall your blood cancer program, and close them before your first patient is enrolled.